Bespoke Circulating Tumor DNA (ctDNA) Analysis as a Predictive Biomarker in Solid Tumor Patients (pts) Treated with Single Agent Pembrolizum

The advent of ultra-sensitive and specific molecular assays has increased the feasibility of circulating tumor DNA (ctDNA) detection.